A Study of Penpulimab Combination Therapy in Patients With Advanced Nasopharyngeal Carcinoma
A Phase II Study of Penpulimab Combined With Chemotherapy ± Anlotinib Hydrochloride in Patients With Advanced Nasopharyngeal Carcinoma
Sponsor: Akeso
Listed as NCT04736810, this PHASE2 trial focuses on Nasopharyngeal Carcinoma and remains completed. Sponsored by Akeso, it has been updated 6 times since 2021, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.
Status Flow
Change History
6 versions recorded-
Apr 2025 — Present [monthly]
Completed PHASE2
-
Sep 2024 — Apr 2025 [monthly]
Completed PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE2
-
May 2024 — Jul 2024 [monthly]
Completed PHASE2
Status: Unknown Status → Completed
-
Jul 2023 — May 2024 [monthly]
Unknown Status PHASE2
Status: Recruiting → Unknown Status
▶ Show 1 earlier version
-
Mar 2021 — Jul 2023 [monthly]
Recruiting PHASE2
First recorded
Feb 2021
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Akeso
- Akeso Tiancheng, Inc
For direct contact, visit the study record on ClinicalTrials.gov .